Kirin Pharma To Close Three Of Four R&D Sites In Japan
This article was originally published in PharmAsia News
Kirin Pharma of Japan says it will close all but one of its R&D sites within the next three years. The firm, a subsidiary of Kirin Holdings, has four such sites in the Gunma Prefecture employing about 200 researchers. The company said the workers would be reassigned as it sells the closing facilities. Kirin R&D work is to be done in conjunction with another subsidiary, Kyowa Hakko Kogyo, after a merger scheduled for October. (Click here for more - a subscription may be required
You may also be interested in...
By outlicensing early-stage compounds, Japanese pharma can gain benefits beyond receiving licensing fees, including de-risking Japanese development, according to a U.S. biotech CEO
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.